APCO Brussels x Health: Back on the Agenda
4 episodes - English - Latest episode: over 3 years ago -Health policy is a hot topic - but there's more to talk about than just coronavirus. In this podcast, APCO Worldwide's Brussels team looks at the European Commission's health priorities - cancer, digital health, access to medicines, and anti-microbial resistance (AMR) - in the wake of COVID-19. With the help of health experts, we'll look at getting these items back on the agenda.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Access to Medicines with Alexander Natz
February 23, 2021 17:00 - 32 minutes - 22.4 MBIn our final episode of the series, we sit down with Alexander Natz, Secretary-General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).
Digital Health with Benedikt Blomeyer and Gözde Susuzlu
December 16, 2020 08:00 - 34 minutes - 23.8 MBIn this episode, we sit down with Benedikt Blomeyer, EU Policy Director at Allied for Startups, and Gözde Susuzlu, Project Coordinator of Data Saves Lives at the European Patients' Forum. For more on the Digital Health, including further contributions from Gözde Susuzlu, follow APCO's recent webinar on the European Health Data Space: https://apcoworldwide.com/blog/how-can-we-make-european-health-data-governance-models-more-patient-centric/
Antimicrobial Resistance (AMR) with Aleks Engel, David Tordrup, and Ghada Zoubiane
November 18, 2020 11:00 - 46 minutes - 32.1 MBIn this episode, we sit down with Aleks Engel, Partner at Novo Holdings, and David Tordrup, a health economist specialising in pharmaceutical policy and access to medicines. We also speak to Ghada Zoubiane, Head of Partnerships and Stakeholder Engagement at ICARS - the International Centre for Antimicrobial Resistance Solutions.
Cancer with Prof. Nils Wilking and MEP Peter Liese
October 21, 2020 13:00 - 32 minutes - 22.2 MBIn this episode, we sit down with Nils Wilking, Associate Professor at the Karolinska Institutet, and an established figure in Swedish clinical oncology, and Peter Liese, a German Member of European Parliament for the EPP group, and one of the leading MEPs on health policy.